Home / Medical Apps / PCSK9 Forum - Lipid Lowering on Windows Pc

PCSK9 Forum - Lipid Lowering on Windows Pc

Developed By: Abannan Digital Solutions

License: Free

Rating: 1,0/5 - 1 votes

Last Updated: December 24, 2023

Compatible with Windows 10/11 PC & Laptop

App Details

Version	1.3.2
Size	29.8 MB
Release Date	May 05, 20
Category	Medical Apps
App Permissions: Allows applications to open network sockets. [see more (10)]
What's New: Bug fixes and performance enhancements; [see more]
Description from Developer: Low density lipoprotein cholesterol (LDL-C) is a major modifiable risk factor driving the development of atherosclerosis and cardiovascular disease (CVD). While statins are effecti... [read more]

App preview ([see all 6 screenshots])

About this app

On this page you can download PCSK9 Forum - Lipid Lowering and install on Windows PC. PCSK9 Forum - Lipid Lowering is free Medical app, developed by Abannan Digital Solutions. Latest version of PCSK9 Forum - Lipid Lowering is 1.3.2, was released on 2020-05-05 (updated on 2023-12-24). Estimated number of the downloads is more than 100. Overall rating of PCSK9 Forum - Lipid Lowering is 1,0. Generally most of the top apps on Android Store have rating of 4+. This app had been rated by 1 users, 1 users had rated it 5*, 1 users had rated it 1*.

How to install PCSK9 Forum - Lipid Lowering on Windows?

Instruction on how to install PCSK9 Forum - Lipid Lowering on Windows 10 Windows 11 PC & Laptop

In this post, I am going to show you how to install PCSK9 Forum - Lipid Lowering on Windows PC by using Android App Player such as BlueStacks, LDPlayer, Nox, KOPlayer, ...

Before you start, you will need to download the APK/XAPK installer file, you can find download button on top of this page. Save it to easy-to-find location.

[Note] You can also download older versions of this app on bottom of this page.

Below you will find a detailed step-by-step guide, but I want to give you a fast overview of how it works. All you need is an emulator that will emulate an Android device on your Windows PC and then you can install applications and use it - you see you're playing it on Android, but this runs not on a smartphone or tablet, it runs on a PC.

If this doesn't work on your PC, or you cannot install, comment here and we will help you!

Install using BlueStacks
Install using NoxPlayer

Step By Step Guide To Install PCSK9 Forum - Lipid Lowering using BlueStacks

Download and Install BlueStacks at: https://www.bluestacks.com. The installation procedure is quite simple. After successful installation, open the Bluestacks emulator. It may take some time to load the Bluestacks app initially. Once it is opened, you should be able to see the Home screen of Bluestacks.
Open the APK/XAPK file: Double-click the APK/XAPK file to launch BlueStacks and install the application. If your APK/XAPK file doesn't automatically open BlueStacks, right-click on it and select Open with... Browse to the BlueStacks. You can also drag-and-drop the APK/XAPK file onto the BlueStacks home screen
Once installed, click "PCSK9 Forum - Lipid Lowering" icon on the home screen to start using, it'll work like a charm :D

[Note 1] For better performance and compatibility, choose BlueStacks 5 Nougat 64-bit read more

[Note 2] about Bluetooth: At the moment, support for Bluetooth is not available on BlueStacks. Hence, apps that require control of Bluetooth may not work on BlueStacks.

How to install PCSK9 Forum - Lipid Lowering on Windows PC using NoxPlayer

Download & Install NoxPlayer at: https://www.bignox.com. The installation is easy to carry out.
Drag the APK/XAPK file to the NoxPlayer interface and drop it to install
The installation process will take place quickly. After successful installation, you can find "PCSK9 Forum - Lipid Lowering" on the home screen of NoxPlayer, just click to open it.

Discussion

(*) is required

Download older versions

Other versions available: 1.3.2.

Download PCSK9 Forum - Lipid Lowering 1.3.2 on Windows PC – 29.8 MB

Low density lipoprotein cholesterol (LDL-C) is a major modifiable risk factor driving the development of atherosclerosis and cardiovascular disease (CVD). While statins are effective in lowering LDL-C, attainment of LDL-C goal is problematic in individuals at high CV risk. These high risk individuals include those with inherited high cholesterol (familial hypercholesterolaemia, FH), established CVD and those unable to tolerate statin therapy, often due to muscle symptoms. New LDL-C lowering therapeutic options are needed to address the unmet clinical needs of these patients.

The discovery of PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein which plays a pivotal role in controlling circulating LDL-C levels, has been the driver for the development of a new class of LDL-C lowering agents. PCSK9 binds to the LDL receptor on the cell and blocks the recycling of LDL receptors, leading to higher LDL-C levels in the plasma. Therefore, inhibiting PCSK9 would lead to increased availability of LDL-C receptors and in turn lower LDL-C levels.

The first agents in this new class, monoclonal antibodies targeting PCSK9 (alirocumab and evolocumab), have recently received regulatory approval in the US and Europe. These agents have been shown to be highly effective in lowering LDL-C levels by more than 50%, on top of statin and other lipid‐lowering treatment, with consistent response across the spectrum of high CV risk patients. PCSK9 inhibitors also lower lipoprotein(a), another established CV risk factor. The PCSK9 monoclonal antibody therapies offer a new approach to getting high CV risk patients to LDL-C goal.

With the advent of this novel therapeutic class, there is a need for an accessible resource which summarises what clinicians need to know about PCSK9. PCSK9 Forum is the independent online resource on PCSK9 science and clinical application, established by leading researchers in the fields of atherosclerosis, lipids and CVD. This Handbook, authored by PCSK9 Forum Editors Professors Chapman and Ginsberg, provides a unique accessible reference for clinicians. The Handbook discusses the biology of PCSK9, and how the development of PCSK9 inhibitors will revolutionise the management of these high CV risk patients, in particular those with FH. The Handbook also provides an overview of the clinical evidence for the most advanced of these novel agents, covering both efficacy and safety. This easy to read, comprehensive resource will help clinicians in their everyday practice to address the unmet clinical needs of patients at high CVD risk.

Bug fixes and performance enhancements;

Allows applications to open network sockets.
Allows applications to access information about networks.
Allows using PowerManager WakeLocks to keep processor from sleeping or screen from dimming.
Allows an application to receive the ACTION_BOOT_COMPLETED that is broadcast after the system finishes booting.
Allows access to the vibrator.
Allows an application to write to external storage.
Allows applications to access information about Wi-Fi networks.
Allows an app to access approximate location.
Allows an app to access precise location.
Allows an application to read from external storage.